RxDoctor Payments Data

Daniel Broadbent, MD

Family Medicine · Farmington, UTNPI 1699901231

Payments from drug & device makers

$6,986in general payments, 2019–2025

Across 440 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$792
  • Novo Nordisk$747
  • Supernus Pharmaceuticals, Inc.$436
  • Lilly USA, LLC$350
  • Amgen$245
  • plus $3K from 51 others

What the payments were for

  • Food & beverage$6,961100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,986 in reported general payments places this provider in the 85th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$79,708
Medicare patients
149
Services billed
2,100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$104,872
FarxigaDapagliflozin Propanediol53$74,899
TrulicityDulaglutide53$63,196
EliquisApixaban32$43,054
Abilify MaintenaAripiprazole12$32,025
JardianceEmpagliflozin26$29,499
XareltoRivaroxaban25$24,590
MyrbetriqMirabegron23$23,137
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$13,767
Tresiba Flextouch U-200Insulin Degludec14$9,354
LinzessLinaclotide11$5,650
BelsomraSuvorexant11$5,139
Buprenorphine14$4,120
Testosterone11$3,935
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$3,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$747$104,87283 claims
AstraZenecaFarxiga$792$74,89953 claims
Lilly USA, LLCTrulicity$350$63,19653 claims
PfizerEliquis$217$43,05432 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$33$32,02512 claims
Boehringer IngelheimJardiance$15$29,49926 claims
Johnson & JohnsonXarelto$132$24,59025 claims
Astellas Pharma US IncMyrbetriq$22$23,13723 claims
GSKTrelegy Ellipta$240$13,76715 claims
AbbVieLinzess$1,491$5,65011 claims
MerckBelsomra$126$5,13911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 928 family medicine providers in Utah.

Other family medicine in Farmington

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →